Disruptive
therapies for
aging diseases
We are a patient-centric clinical-stage biotech company dedicated to developing disruptive therapies for aging diseases.
Our innovative technology platform features novel dual-action drugs that elevate cGMP levels to enhance microcirculation, promote tissue regeneration, and prevent local oxygen deficiency. With this cutting-edge approach, we are dedicated to delivering transformative therapies across regenerative medicine, medical cosmetics, oncology, ophthalmology, and fibrosis.
We are focusing on topical local administration of our substances to achieve an optimal combination of efficacy and safety in combination with long-lasting durable activity profiles. This is reflected in our company’s name TOPADUR.
TOPADUR Pharma AG was founded in 2015 with its head quarter located in Schlieren, Switzerland. So far we have successfully acquired 33M USD in private equity resulting in a broad portfolio of patent protected substances. Our lead substance TOP-N53 is currently in clinical development for topical treatment of digital ulcers in systemic sclerosis patients. We are currently embarking on Series C2 in our investigation strategy aiming for an IPO in the following phase.
“We strive to improve and enhance the quality oflife. Our team possesses a wealth of experience in health sciences, allowing usto navigate the industry's challenges with expertise and insight.”
Reto Naef, founder, chair of the board of directors and CEO a.i.
Founder | CEO a.i.
Founder | CEO a.i.
Reto Naef is the founder and Chief Executive Officer (CEO) a.i. of TOPADUR Pharma AG. He has more than 30 years of leadership experience in the pharmaceutical industry. He is author of 15 patents and made key contributions to several drugs on the market. Dr. Naef holds a PhD in chemistry from the ETH Zurich and an MBA from the University of Zurich.
CIO | Deputy CEO a.i.
CIO | Deputy CEO a.i.
Matthias Schäfer is Chief Innovation Officer (CIO) and Deputy CEO a.i. He brings over 20 years of experience in the Life Science sector. As seasoned international executive he combines management and in-depth research skills. PD Dr. Schäfer is also a consultant and a lecturer at the ETH Zurich. He holds a PhD in Biology and has (co-)authored more than 40 peer-reviewed publications.
CFO a.i.
CFO a.i.
Cornelia Gehrig is the Chief Finance Officer (CFO) a.i. with many years of experience as Group CFO in international companies across various industries. She has proven expertise in the areas of finance, audit, risk management, strategy, business transformation, M&A, and change management. Education: Master in Economics from University Bern (lic.rer.pol) and Certified Public Accountant.
CRO
CRO
Jay Siegel is the Chief Research Officer (CRO). He has more than 40 years of experience in molecular design and chemical synthesis research. Prof. Siegel held several professor and director positions at renowned research institutions. He is most recently Senior Advisor to the President of the University of Hong Kong. He holds a PhD in Chemistry from Princeton University.
Head of Research | Medical Director
Head of Research | Medical Director
Hermann Tenor is the Chief Science Officer (CSO). He accumulates over 25 years of industrial drug discovery and development experience. Dr. Tenor was involved in the non-clinical characterization of a first-in-class marketed product. He is co-author of 50 scientific publications and holds an MD from the Martin-Luther University Halle Wittenberg.
CDO | Head of Legal
CDO | Head of Legal
Christian Ludin is the Chief Development Officer (CDO). He has more than 20 years of experience in preclinical and clinical drug development. Dr. Ludin is co-inventor of 13 patents and author of 15 publications and made significant contributions to the development of several drug candidates. He holds a PhD in Chemistry from the University of Freiburg i. B. and an LLM in Law from the University of Zurich.
Chair since 2015
Chair since 2015
Member since 2020
Member since 2020
Member since 2018
Member since 2018
Member since 2020
Member since 2020
Member since 2015
Member since 2015
Member since 2024
Member since 2024
• Material Board Mandates:
Listed: ARYZTA AG, SKAN Group AG Not listed: Koras AG, Ernst Schweizer AG
• Founder & Owner Cornelia Gehrig GmbH
Since 2021
Member since 2015
Member since 2015
Secretary of the Board
Secretary of the Board
“We’re on the lookout for outstanding teammembers who are bursting with curiosity, motivation, and passion! If you'reready to make an impact and bring your unique spark to our dynamic team, wewant to hear from you!”
Cornelia Gehrig, Chief Finance Officer a.i.
